Abstract：
UNASSIGNED: Biologics have revolutionized psoriasis treatment; however, relapse of psoriasis after discontinuation of biologics remains unresolved.
UNASSIGNED: To assess the impact of adjunctive Chinese medicine (CM) therapy on relapse of psoriasis vulgaris (PV) after discontinuation of biologics.
UNASSIGNED: We constructed a prospective cohort study through a psoriasis case registry platform that enrolled patients treated with biologics (in combination with or without CM). The endpoint event was relapse, defined as loss of psoriasis area and severity index (PASI) 75.
UNASSIGNED: A total of 391 patients completed the study and were included in the analysis, of whom 169 (43.2%) experienced relapse during follow-up. To minimize the bias, a 1:1 propensity score matching (PSM) was performed, generating matched cohorts of 156 individuals per group. Adjuvant CM therapy significantly associated with reduced incidence of relapse (HR =0.418, 95% CI = 0.289 ∼ 0.604, p < 0.001), and the protective effect of CM in the subgroup analysis was significant. In addition, PASI 90 response and disease duration were associated with relapse (p < 0.05).
UNASSIGNED: Adjunctive CM therapy is associated with reduced relapse incidence in PV after discontinuation of biologics.
UNASSIGNED: To assess the impact of adjunctive Chinese medicine (CM) therapy on relapse of psoriasis vulgaris (PV) after discontinuation of biologics.
UNASSIGNED: We constructed a prospective cohort study through a psoriasis case registry platform that enrolled patients treated with biologics (in combination with or without CM). The endpoint event was relapse, defined as loss of psoriasis area and severity index (PASI) 75.
UNASSIGNED: A total of 391 patients completed the study and were included in the analysis, of whom 169 (43.2%) experienced relapse during follow-up. To minimize the bias, a 1:1 propensity score matching (PSM) was performed, generating matched cohorts of 156 individuals per group. Adjuvant CM therapy significantly associated with reduced incidence of relapse (HR =0.418, 95% CI = 0.289 ∼ 0.604, p < 0.001), and the protective effect of CM in the subgroup analysis was significant. In addition, PASI 90 response and disease duration were associated with relapse (p < 0.05).
UNASSIGNED: Adjunctive CM therapy is associated with reduced relapse incidence in PV after discontinuation of biologics.
摘要：
■生物制剂彻底改变了牛皮癣的治疗方法；然而，停用生物制剂后银屑病的复发仍未解决.
■评估生物制剂停药后中药（CM）辅助治疗对寻常型银屑病（PV）复发的影响。
■我们通过银屑病病例注册平台构建了一项前瞻性队列研究，该研究招募了接受生物制剂治疗（联合或不联合CM）的患者。终点事件为复发，定义为牛皮癣面积损失和严重程度指数（PASI）75。
■共有391名患者完成了研究并被纳入分析，其中169人(43.2%)在随访期间复发.为了最小化偏差，进行1：1倾向评分匹配(PSM)，生成每组156名个体的匹配队列。辅助CM治疗与复发率降低显著相关(HR=0.418,95%CI=0.289~0.604,p<0.001),亚组分析中CM的保护作用显著。此外,PASI90反应和疾病持续时间与复发相关(p<0.05)。
■辅助CM治疗与生物制剂停药后PV复发率降低相关。
■评估生物制剂停药后中药（CM）辅助治疗对寻常型银屑病（PV）复发的影响。
■我们通过银屑病病例注册平台构建了一项前瞻性队列研究，该研究招募了接受生物制剂治疗（联合或不联合CM）的患者。终点事件为复发，定义为牛皮癣面积损失和严重程度指数（PASI）75。
■共有391名患者完成了研究并被纳入分析，其中169人(43.2%)在随访期间复发.为了最小化偏差，进行1：1倾向评分匹配(PSM)，生成每组156名个体的匹配队列。辅助CM治疗与复发率降低显著相关(HR=0.418,95%CI=0.289~0.604,p<0.001),亚组分析中CM的保护作用显著。此外,PASI90反应和疾病持续时间与复发相关(p<0.05)。
■辅助CM治疗与生物制剂停药后PV复发率降低相关。
